lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
242 rows where filing_period = "second_quarter", filing_year = 2016 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1836727 | AMERICAN COLLEGE OF CLINICAL PHARMACY 0edeb597-7089-4032-a4b9-a64567211685 | Q2 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2016 | second_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 128875 | 0 | 0 | 2016-06-27T14:58:27.203000-04:00 | |
| 1836741 | NAHIGIAN STRATEGIES, LLC afcce0f2-b73c-43bb-8a0c-5332cacb37ba | Q2 | NAHIGIAN STRATEGIES, LLC | 322897 | TEVA PHARMACEUTICALS USA INC | 2016 | second_quarter | PHA | Advocate for pathway to improving existing therapies. | 45000 | 0 | 0 | 2016-06-28T13:57:51.087000-04:00 | ||
| 1837009 | HANCE SCARBOROUGH 6a44c87a-f5ba-4cc7-b1a4-8ddd8de002d7 | Q2 | HANCE SCARBOROUGH | 17443 | ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS | 2016 | second_quarter | PHA | Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2016-07-01T13:22:21.393000-04:00 | ||
| 1837045 | PD FRAZER CONSULTING, INC. f53c32dd-e611-4410-8ebc-5ef5b03cd8b4 | Q2 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2016 | second_quarter | PHA | Monitor the development of proposed bills about the importation of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2016-07-01T14:18:17.867000-04:00 | |
| 1837069 | AMERICAN AMBULANCE ASSOCIATION 37a058e5-535b-475f-9603-c1ccd29671e0 | Q2 | AMERICAN AMBULANCE ASSOCIATION | 56018 | AMERICAN AMBULANCE ASSOCIATION | 2016 | second_quarter | PHA | Lobbied in support of the Protecting Patient Access to Emergency Medications Act (H.R. 4365, S. 2932) to ensure the continuity of standing orders for the administration of certain controlled substances by paramedics and EMTs to patients. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 300000 | 0 | 0 | 2016-07-01T15:29:10.813000-04:00 | |
| 1837920 | MR. BRIAN KELLY b69a4444-d0f5-4d0a-8e27-16042cd3ba03 | Q2 | MR. BRIAN KELLY | 40024191 | LUNDBECK PHARMACEUTICALS | 2016 | second_quarter | PHA | FDA Reform | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2016-07-06T18:12:37.517000-04:00 | |
| 1838112 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) a1cab4c7-5f09-4571-b66d-b6c9090550b6 | Q2 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 400265214 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 2016 | second_quarter | PHA | Issues related to pharmaceutical pricing and federal oversight by the FDA | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 198893 | 0 | 0 | 2016-07-07T12:04:14.517000-04:00 | |
| 1838174 | KATE MOSS f9bc1983-2b02-47fe-a05d-f19aea135280 | Q2 | KATE MOSS | 25988 | CVS HEALTH | 2016 | second_quarter | PHA | Issues related to prescription drug abuse and drug supply chain safety. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2016-07-07T13:31:54.167000-04:00 | |
| 1838506 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 067682ad-7584-4460-9eb3-e84d9656dffb | Q2 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2016 | second_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 270000 | 0 | 0 | 2016-07-08T10:58:29.223000-04:00 | |
| 1838595 | PARRY, ROMANI, DECONCINI & SYMMS cb572958-310d-46a2-bacf-eb8efd1f28ee | Q2 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 18000 | 0 | 0 | 2016-07-08T12:32:19.500000-04:00 | |
| 1838605 | ROCK & ASSOCIATES 94228fcc-3f31-4b39-a180-1405611a36e2 | Q2 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2016-07-08T12:50:37.927000-04:00 | |
| 1838616 | ROCK & ASSOCIATES ddf4d1f3-b7ce-43ea-b76b-d1493d69a6de | Q2 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2016-07-08T12:55:53.877000-04:00 | |
| 1838621 | ROCK & ASSOCIATES 03f44bee-dcea-4949-a095-ae3655093cb0 | Q2 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2016-07-08T12:58:56.457000-04:00 | |
| 1838623 | ROCK & ASSOCIATES d0891db2-677d-4b9c-bf26-5cf452e5b46a | Q2 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2016-07-08T13:02:58.443000-04:00 | |
| 1838630 | ROCK & ASSOCIATES b6774d34-19ae-4eac-899b-4023271eacff | Q2 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2016-07-08T13:11:05.160000-04:00 | |
| 1838648 | ROCK & ASSOCIATES 0cfb999b-919a-4979-9100-ecbffebe6bdf | Q2 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2016 | second_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2016-07-08T13:24:24.133000-04:00 | |
| 1838826 | HOLLAND & KNIGHT LLP 15d2dfeb-e74b-473a-85f6-89cf4bedf214 | Q2 | HOLLAND & KNIGHT LLP | 18466 | PROTECTING ACCESS TO PAIN RELIEF COALITION | 2016 | second_quarter | PHA | Advocating for policy to ensure patient access to pain relief. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-08T17:02:50.110000-04:00 | |
| 1838829 | HOLLAND & KNIGHT LLP b595a7cf-194b-4146-87f4-3b6057207002 | Q2 | HOLLAND & KNIGHT LLP | 18466 | THE BIOSIMILARS FORUM | 2016 | second_quarter | PHA | Medicare reimbursement issues, FDA regulation of biosimilars. | HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2016-07-08T17:06:56.063000-04:00 | |
| 1838967 | INDEPENDENT PHARMACY COOPERATIVE 7fe05fd2-dd12-403a-a959-27dd10834c16 | Q2 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2016 | second_quarter | PHA | H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. S.524 Comprehensive Addiction and Recovery Act of 2016. IPC is against as currently written. Actual Acquisition Cost (AAC) adoption with state Medicaid programs. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-10T12:56:24.813000-04:00 | |
| 1839311 | RED+BLUE STRATEGIES c92f3e28-6271-47f0-af4f-4fbcbc64c226 | Q2 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2016 | second_quarter | PHA | National Defense Authorization Act of FY 2017 - Work to ensure that the current treatment of mail order for retired and active military personnel and their families remains constant in the pending Authorization bill. The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to mail order coverage for Medicare, Medicaid, Exchanges, Tricare and other programs. Issues related to the pricing of prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-11T14:43:45.277000-04:00 | |
| 1839415 | RED+BLUE STRATEGIES df4dd265-b009-4528-b14f-b06f301631e1 | Q2 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2016 | second_quarter | PHA | The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-11T15:38:54.563000-04:00 | |
| 1840272 | THORSEN FRENCH ADVOCACY LLC 6b759bb6-a087-42f9-ab1a-86635b13acd5 | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | CARDINAL HEALTH, INC. | 2016 | second_quarter | PHA | Issues related to prescription drug abuse. Issues related to pharmaceutical market value. S.524: Comprehensive Addiction and Recovery Act (CARA). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2016-07-12T14:48:24.890000-04:00 | |
| 1840298 | THORSEN FRENCH ADVOCACY LLC 390ad1ff-13e1-4742-bae5-bffb3566c217 | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2016 | second_quarter | PHA | Issues related to pharmaceutical market value. Issues related to prescription drug abuse. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-12T15:05:59.347000-04:00 | |
| 1840322 | NELSON MULLINS RILEY & SCARBOROUGH e7a63a14-eaf9-4675-a7d0-42b90d1adb69 | Q2 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) | 2016 | second_quarter | PHA | Any legislation and regulation to the treatment of opioid abuse. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-12T15:12:12.267000-04:00 | |
| 1840666 | THORSEN FRENCH ADVOCACY LLC 175aa0d4-5f00-4bed-ad56-6b964efc3b5f | Q2 | THORSEN FRENCH ADVOCACY LLC | 400599826 | HEALTHCARE DISTRIBUTION ALLIANCE | 2016 | second_quarter | PHA | General issues related to prescription drug abuse. Issues related to pharmaceutical market value. S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016. H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2016. S. 524: Comprehensive Addiction and Recovery Act of 2016. H.R. 953: Comprehensive Addiction and Recovery Act of 2016. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-13T09:33:39.750000-04:00 | |
| 1840758 | FLYNN & ASSOCIATES, INC. d35fda00-a374-4a52-b698-547e2c9a9ddb | Q2 | FLYNN & ASSOCIATES, INC. | 15020 | PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION | 2016 | second_quarter | PHA | Medicare Part-D rebates Trade agreements Patent reform issues Medicare Part-B Doctor reimbursement regulations | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-13T10:21:57.317000-04:00 | |
| 1841487 | CONNECT 4 STRATEGIES, LLC b9b8bdfe-04f0-4c96-a1b2-d6f632ab7648 | Q2 | CONNECT 4 STRATEGIES, LLC | 401103720 | BIOMARIN PHARMACEUTICAL INC. | 2016 | second_quarter | PHA | Rare pediatric review voucher. S 1878 and HR 1537 | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2016-07-13T21:01:52.910000-04:00 | |
| 1841915 | WILLIAMS AND JENSEN, PLLC 058222fb-b5c3-4eca-9b46-8cf0a5a2034e | Q2 | WILLIAMS AND JENSEN, PLLC | 41454 | FAGRON NORTH AMERICA | 2016 | second_quarter | PHA | Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-14T11:35:49.890000-04:00 | |
| 1841984 | MCDERMOTT+ LLC adb2ce76-5651-4f15-a586-741c83779771 | Q2 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2016 | second_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-14T11:57:51.393000-04:00 | |
| 1842024 | MCDERMOTT+ LLC a0e57cb3-ec2c-4abb-b077-effb0b7aa92f | 2A | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2016 | second_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-14T12:10:29.833000-04:00 | |
| 1842929 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 9680354d-7e7e-4a06-bc39-ce241c59e169 | Q2 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2016 | second_quarter | PHA | Proposals relating to the regulation of direct to consumer prescription drug advertising H.R. 4565, Responsibility in Drug Advertising Act of 2016, to prohibit for three years after FDA approval direct to consumer prescription drug advertising | Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,SENATE | 420000 | 0 | 0 | 2016-07-15T09:53:22.737000-04:00 | |
| 1842936 | POWERS PYLES SUTTER & VERVILLE, P.C. eb5d011a-1123-4586-9209-15be2eb320ae | Q2 | POWERS PYLES SUTTER & VERVILLE, P.C. | 32008 | 340B HEALTH | 2016 | second_quarter | PHA | Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3) funding of the Health Resources and Services Administration (HRSA)under the Labor Health & Human Services & Education appropriations bills. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-15T09:53:24.817000-04:00 | |
| 1843030 | ACADEMY OF MANAGED CARE PHARMACY 26eae006-e062-4964-a08c-89ae33cdd346 | Q2 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2016 | second_quarter | PHA | Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy, providing comments to the FDA on the impact of Risk Evaluation Mitigation Strategies (REMS), supporting H.R. 2841 designed to increase access to generic drugs and providing comments to CMS on benefit and payment parameters for 2017. Support S. 524 (CARA). Comments provided to SAMSHA and AHRQ on opioid abuse. Comments provided on S. 2700 concerning an exemption for biological medicines from USP standards for quality. Comments provided to CMS on MACRA proposed rule. | Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 188000 | 0 | 0 | 2016-07-15T10:33:58.977000-04:00 | |
| 1843052 | KENT & O'CONNOR, INC. 238b9bf1-a7e0-4a5d-a311-49361bcd5c40 | Q2 | KENT & O'CONNOR, INC. | 21426 | INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION | 2016 | second_quarter | PHA | Legislation and regulations relating to drug and safety issues. | Consumer Product Safety Commission (CPSC),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),U.S. Customs & Border Protection | 30000 | 0 | 0 | 2016-07-15T10:39:21.180000-04:00 | |
| 1843093 | WAXMAN STRATEGIES ff107c8f-167c-4df4-99d2-a1497d15b528 | Q2 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2016 | second_quarter | PHA | Laws and regulations affecting the 340B Drug Discount Program | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,White House Office | 18750 | 0 | 0 | 2016-07-15T10:45:51.807000-04:00 | |
| 1843184 | CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES) b252cdbe-f441-422f-97c0-b2df93b77a9e | Q2 | CAPVIEW ASSOCIATES LLC (DBA CAPVIEW STRATEGIES) | 401103546 | PFIZER INC. | 2016 | second_quarter | PHA | Issues related to the value of pharmaceuticals including developing sustainable models that support innovation. | Centers For Medicare and Medicaid Services (CMS),Medicare Payment Advisory Commission (MedPAC) | 20000 | 0 | 0 | 2016-07-15T11:13:22.980000-04:00 | |
| 1843475 | NELSON MULLINS RILEY & SCARBOROUGH 6cedafc4-aba2-4fe8-b2f0-74749f3861af | Q2 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | CASCADE HEMOPHILIA CONSORTIUM | 2016 | second_quarter | PHA | Issues related to 340B Drug Pricing Progam | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-15T12:42:01.053000-04:00 | |
| 1843771 | WINNING STRATEGIES WASHINGTON 8bf8a1f1-237c-4134-b6c5-c08b6d353ca4 | Q2 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2016 | second_quarter | PHA | Pharmaceutical drug development, Reducing opiod overdose deaths and S. 707; H.R. 3680 provisions related to Nalaxone; S. 2256 provisions related to Nalaxone | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-15T14:13:01.570000-04:00 | |
| 1844049 | NELSON MULLINS RILEY & SCARBOROUGH 6a911653-7b83-4124-b1f3-45d6e38bd5b6 | Q2 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2016 | second_quarter | PHA | Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-15T15:26:18.627000-04:00 | |
| 1844188 | CARD & ASSOCIATES, LLC 4bb7de4c-7320-4147-800d-ad220cbd7f11 | Q2 | CARD & ASSOCIATES, LLC | 84217 | AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) | 2016 | second_quarter | PHA | Educate Members on pharmacy contracting with pharmacy benefit managers | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2016-07-15T15:42:13.287000-04:00 | |
| 1844243 | CARD & ASSOCIATES, LLC 3e18eb93-42ef-4b88-bcac-fd435ad41115 | 2T | CARD & ASSOCIATES, LLC | 84217 | CLOAKROOM ADVISORS LLC ON BEHALF OF LINDEN CARE LLC | 2016 | second_quarter | PHA | Educate Members on pharmacy contracting with pharmacy benefit managers | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 1 | 2016-07-15T15:49:18.037000-04:00 | |
| 1844367 | BLUECROSS BLUESHIELD OF TENNESSEE a9543602-fd43-4782-acbb-685e43d3524e | Q2 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2016 | second_quarter | PHA | General Pharmacy Issues; HR6, 21st Century Cures; opioid abuse (S. 524); specialty drug pricing | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-15T16:26:30.650000-04:00 | |
| 1844616 | COVINGTON & BURLING LLP ce47f067-bc7b-44cb-a8bd-357aa78c16b3 | Q2 | COVINGTON & BURLING LLP | 11195 | MEDIMETRIKS PHARMACEUTICALS INC | 2016 | second_quarter | PHA | Regulation of marketed unapproved drugs | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2016-07-15T19:13:18.887000-04:00 | |
| 1844617 | COVINGTON & BURLING LLP 1fdfbfcf-bb2e-43dd-abd9-aa5b2811ce32 | Q2 | COVINGTON & BURLING LLP | 11195 | FABRE-KRAMER PHARMACEUTICALS, INC | 2016 | second_quarter | PHA | Policy regarding demonstration of effectiveness for new drug approvals. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2016-07-15T19:14:22.717000-04:00 | ||
| 1844630 | OREGON HEALTH & SCIENCE UNIVERSITY ebf9c8c4-e988-4551-898c-5580efeb180e | Q2 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2016 | second_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-15T19:24:35.170000-04:00 | |
| 1844663 | THE D MAJOR GROUP a22c820a-8458-4203-9ef5-d6d90e37017f | Q2 | THE D MAJOR GROUP | 401103162 | CVS CAREMARK | 2016 | second_quarter | PHA | Issues related to pharmacy delivery including S. 2615, The Increasing Competition in Pharmaceuticals Act. Also monitor matters related to H.R. 244, The MAC Transparency Act. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-16T09:14:44.140000-04:00 | |
| 1845234 | ALKERMES, INC. 5aca04a8-7bf2-47cb-8c10-2a1686d0b609 | Q2 | ALKERMES, INC. | 400458235 | ALKERMES, INC. | 2016 | second_quarter | PHA | Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 6 the 21st Century Cures Act | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA) | 1340000 | 0 | 0 | 2016-07-18T10:25:12.713000-04:00 | |
| 1845271 | RED+BLUE STRATEGIES 29732d19-0f0c-4fe8-a3b3-62513dc9db88 | Q2 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2016 | second_quarter | PHA | S. 524 - The Comprehensive Addiction and Recovery Act - supporting efforts to fight opioid abuse in the United States. Work focused on the inclusion of "lock in" programs in the Medicare program to prevent and protect seniors from opioid addiction. S.185 - The Promise for Antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. S. 2153 - Provider Payment Sunshine Act - policies supporting the inclusion of all prescribers to the Open Payments program. H.R. 5054 - Agriculture Appropriations Bill for FY 2017 - Issues related to FDA treatment of antibiotics and compounding of certain pharmaceuticals. Legislative and regulatory issues surrounding unique device identifiers (UDI) being addressed by CMS, FDA and ONC. Advancing provisions to highlight Antibiotic Innovation and combating prescription drug abuse in the President's FY 2017 budget. Supporting policies to maintain the integrity of laws regarding compounding of certain medications. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. | Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2016-07-18T10:31:34.363000-04:00 | |
| 1845765 | CHAMBER HILL STRATEGIES 80764e92-5bdb-46a4-9eb2-5f26396bb603 | Q2 | CHAMBER HILL STRATEGIES | 400645947 | AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL) | 2016 | second_quarter | PHA | Implementation issues related to P.L. 113-54, the Drug Quality and Security Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-18T11:51:36.337000-04:00 | |
| 1845846 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. c6868ce5-938c-4f8f-b021-4cf89838e1c3 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2016 | second_quarter | PHA | HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2016-07-18T12:06:04.823000-04:00 | |
| 1845867 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. df1bc0ee-9d61-4d2f-9fe7-2f3f16a94444 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2016 | second_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE | 50000 | 0 | 0 | 2016-07-18T12:08:20.573000-04:00 | |
| 1845872 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 7af41366-5d63-457b-bc86-31e38d0c86b5 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2016 | second_quarter | PHA | issues related to the 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-18T12:09:26.493000-04:00 | |
| 1845880 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. b1df74f8-65ed-4a00-a8df-ddeeb1872fd7 | Q2 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2016 | second_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2016-07-18T12:10:31.277000-04:00 | |
| 1845943 | UNIVERSITY OF IOWA 54b8b8c6-6f22-4e9d-bf68-2635c76fd979 | Q2 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2016 | second_quarter | PHA | Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals | Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT) | 86662 | 0 | 0 | 2016-07-18T12:19:28.590000-04:00 | |
| 1846275 | JOHNS HOPKINS UNIVERSITY 74c4656e-2819-4e66-bded-ba00d8691c3f | Q2 | JOHNS HOPKINS UNIVERSITY | 20664 | JOHNS HOPKINS UNIVERSITY | 2016 | second_quarter | PHA | Pharmaceutical drug price increases; 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2016-07-18T13:25:09.723000-04:00 | |
| 1846512 | THE INGRAM GROUP LLC 665dc021-2621-4551-848a-e77b9cebc5cf | Q2 | THE INGRAM GROUP LLC | 400577737 | ELI LILLY AND COMPANY | 2016 | second_quarter | PHA | S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015. H.R.6, 21st Century Cures Act. General issues related to the biopharmaceutical and pharmaceutical industries. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2016-07-18T14:05:33.757000-04:00 | |
| 1846758 | MASSACHUSETTS MEDICAL SOCIETY 8489cc49-dc25-47b5-ab37-654505d1199a | Q2 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2016 | second_quarter | PHA | Prescription Drug Pricing - no specific bill Direct to Consumer Advertising - no specific bill Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill | Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA) | 80000 | 0 | 0 | 2016-07-18T15:27:09.190000-04:00 | |
| 1846855 | UNIVERSITY OF PITTSBURGH MEDICAL CENTER 2dcba39b-15ae-4b86-ad11-dfe92b69b013 | Q2 | UNIVERSITY OF PITTSBURGH MEDICAL CENTER | 32065 | UNIVERSITY OF PITTSBURGH MEDICAL CENTER | 2016 | second_quarter | PHA | Urge Congress to oppose cuts to the 340B program and address the escalation in drug prices. | HOUSE OF REPRESENTATIVES,SENATE | 250000 | 0 | 0 | 2016-07-18T15:52:37.757000-04:00 | |
| 1847189 | SAFEWAY INC. 6af08e0d-e1ba-453a-88ec-277e74ddd1d7 | Q2 | SAFEWAY INC. | 300173 | SAFEWAY | 2016 | second_quarter | PHA | H.R. 592/S. 314, Pharmacy and Underserved Areas Enhancement Act, all provisions. H.R. 4909, FY 2017 National Defense Authorization Act, provisions related to TRICARE and pharmacy access. H.R. 953/S. 524, Comprehensive Addition and Recovery Act, provisions related to state prescription drug monitoring programs. H.R. 793/S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, all provisions. H.R. 3250, DXM Abuse Prevention Act, provisions related to retail pharmacy. | HOUSE OF REPRESENTATIVES,SENATE | 150000 | 0 | 0 | 2016-07-18T17:02:25.027000-04:00 | |
| 1847427 | ACG ADVOCACY 63a376a9-d468-4e89-b5d0-42394adfb994 | Q2 | ACG ADVOCACY | 2057 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2016 | second_quarter | PHA | Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-18T17:44:40.753000-04:00 | |
| 1847438 | PRIME POLICY GROUP f20dbb44-0013-4986-bbca-0df65bd1e620 | Q2 | PRIME POLICY GROUP | 400532589 | GLAXOSMITHKLINE | 2016 | second_quarter | PHA | Drug Pricing | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 40000 | 0 | 0 | 2016-07-18T17:47:59.330000-04:00 | |
| 1847598 | APOTEX CORP. fd7695bd-07d2-4194-9dda-61ae50c12fb5 | Q2 | APOTEX CORP. | 310973 | APOTEX CORP. | 2016 | second_quarter | PHA | H.R. 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S. 3056, the CREATES Act, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; Federal policy relating to the approval of pending abbreviated new drug applications for generic versions of Crestor; and S. 1137, The Patent Act, Technical corrections to the Leahy-Smith American Invents Act and other improvements, provisions in Section 14 relating to the inter partes review process, including federal policy relating to the use of inter partes review challenges of pharmaceutical and biotechnology patents. | HOUSE OF REPRESENTATIVES,SENATE | 230000 | 0 | 0 | 2016-07-18T18:14:24.943000-04:00 | |
| 1847683 | THE MATHIS HARPLE GROUP df04e325-4651-461f-bad2-1fb3ac058d26 | Q2 | THE MATHIS HARPLE GROUP | 322911 | PILMA | 2016 | second_quarter | PHA | Patent Protection; 12 Year Data Exclusivity; TPP | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-18T18:45:00.103000-04:00 | |
| 1847930 | THORN RUN PARTNERS 31315aad-6294-4335-9a48-a39666db62b9 | Q2 | THORN RUN PARTNERS | 400534596 | EXPRESS SCRIPTS, INC. | 2016 | second_quarter | PHA | H.R.244, MAC Transparency Act; pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. S.2943/H.R.4909, National Defense Authorization Act for Fiscal Year 2017; provision authorizing a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-18T22:42:59.460000-04:00 | |
| 1847983 | NOVO NORDISK INC. fc0c0ed0-1243-4649-91c3-694b07e4ea97 | Q2 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2016 | second_quarter | PHA | P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Indian Health Service,Labor, Dept of (DOL),Natl Institutes of Health (NIH),SENATE,Treasury, Dept of | 690000 | 0 | 0 | 2016-07-18T23:50:11.297000-04:00 | |
| 1848610 | AMERICAN VETERINARY MEDICAL ASSOCIATION 2c69cbdb-c866-4ac2-8e35-30ca14413318 | Q2 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2016 | second_quarter | PHA | Discussions with Congressional staff and FDA to express the need for compounding of medications for use in animals and FDA's draft GFI #230 H.R. 3174/S. 1200, the Fairness to Pet Owners Act (Veterinary Compounding Legislation.) Discussions with DEA regarding use of controlled substances by veterinary practitioners. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE | 200000 | 0 | 0 | 2016-07-19T09:17:18.740000-04:00 | |
| 1848710 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 63112824-6b7f-4623-a93d-8606bd58edf4 | Q2 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2016 | second_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Extended Producer Responsibility/Pharmaceutical Stewardship (Drug Take-Back) H.R. 4931 - Pharmaceutical Stewardship Act of 2016. Requires the Drug Enforcement Administration to establish and implement a national pharmaceutical stewardship program to collect and dispose of prescription medications; all sections. H.R. 5046 - Comprehensive Opioid Abuse Reduction Act of 2016 (COARA). Amends the Omnibus Crime Control and Safe Streets Act of 1968 to authorize the Attorney General to make grants to assist State and local governments in addressing the national epidemic of opioid abuse, and for other purposes (all sections). S. 524 - Comprehensive Addiction and Recovery Act of 2016 (CARA). Authorizes the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes (Section 201 - expands eligible uses of grant funds to include drug take-back efforts; Section 203 requires coordination among multiple government agencies to develop a prescription drug take-back program). Oral Contraceptives H.R. 5138 - Over-the-Counter Contraceptives Act of 2016. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. H.… | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 280000 | 0 | 0 | 2016-07-19T09:42:23.713000-04:00 | |
| 1848995 | PRIME THERAPEUTICS d2cedf17-4b57-4837-aafa-68d13ead1774 | Q2 | PRIME THERAPEUTICS | 400339576 | PRIME THERAPEUTICS | 2016 | second_quarter | PHA | S.524: Comprehensive Addiction and Recovery Act, focused on Prescription Drug Management Plans (PDMPs), Medicare lock-in, partial fills and co-prescribing. S.480/H.R.1725: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2015, educating on the importance of PDMPs and the need for federal funding. H.R.4981: The Opioid Use Disorder Treatment Expansion and Modernization Act. H.R.4599/S.2578: Reducing Unused Medications Act of 2016. H.R.3680: Co-Prescribing to Reduce Overdoses Act of 2016. S.2256: Co-Prescribing Saves Lives Act of 2016. H.R.4784: Lower Drug Costs Through Competition Act, support increasing generic availability. S.2680: A bill to amend the Public Health Service Act to provide comprehensive mental health reform, and for other purposes. S.2615: the Increasing Competition in Pharmaceuticals Act. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-19T10:18:56.467000-04:00 | |
| 1849211 | BROWN RUDNICK LLP 2d92dbd8-da15-47f0-9466-1979383c1419 | Q2 | BROWN RUDNICK LLP | 287895 | PRIME THERAPEUTICS | 2016 | second_quarter | PHA | HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA) | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-19T10:41:21.533000-04:00 | |
| 1849229 | BROWN RUDNICK LLP 0223fb13-1f60-44cf-a7e2-d343bc690d42 | Q2 | BROWN RUDNICK LLP | 287895 | EXELA HOLDINGS, LLC | 2016 | second_quarter | PHA | Federal policy relating to pharmaceutical pricing and FDA application review protocols | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2016-07-19T10:43:31.690000-04:00 | |
| 1849253 | BROWN RUDNICK LLP eb0deac6-ddca-4a1b-9b37-d9a488dc84d7 | Q2 | BROWN RUDNICK LLP | 287895 | AMNEAL PHARMACEUTICALS | 2016 | second_quarter | PHA | HR 4981 -Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4976 - Opioid Review Modernization Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA) | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2016-07-19T10:45:48-04:00 | |
| 1849460 | RUBICON ADVISORS, LLC cfd9bef4-87fe-4f97-b0d2-c46248f9074d | Q2 | RUBICON ADVISORS, LLC | 315091 | TEVA PHARMACEUTICALS USA | 2016 | second_quarter | PHA | 21st Century Cures Act | HOUSE OF REPRESENTATIVES,SENATE | 105000 | 0 | 0 | 2016-07-19T11:06:40.130000-04:00 | |
| 1849494 | RUBICON ADVISORS, LLC b839e714-adb5-4f9d-b762-a9533ed7b1d7 | Q2 | RUBICON ADVISORS, LLC | 315091 | OFFICE OF GOVERNOR NATHAN DEAL | 2016 | second_quarter | PHA | Pharmaceuticals HR 707, Restoration of America's Wire Act | HOUSE OF REPRESENTATIVES,SENATE | 43750 | 0 | 0 | 2016-07-19T11:08:59.020000-04:00 | |
| 1849545 | RUBICON ADVISORS, LLC d3c5381b-122c-42f9-9c67-2564a762b740 | Q2 | RUBICON ADVISORS, LLC | 315091 | DYNAVAX TECHNOLOGIES | 2016 | second_quarter | PHA | Pharmaceuticals | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2016-07-19T11:13:37.427000-04:00 | |
| 1849565 | RUBICON ADVISORS, LLC c8552669-ad4b-4b49-bf72-b63c37a0cfff | Q2 | RUBICON ADVISORS, LLC | 315091 | ALLIANCE TO PREVENT THE ABUSE OF MEDICINES | 2016 | second_quarter | PHA | Prescription drug abuse policy | HOUSE OF REPRESENTATIVES,SENATE | 52500 | 0 | 0 | 2016-07-19T11:14:54.257000-04:00 | |
| 1849595 | RUBICON ADVISORS, LLC 92b07ffd-fd0f-405f-961c-7b044d6e3605 | Q2 | RUBICON ADVISORS, LLC | 315091 | COLLEGE OF AMERICAN PATHOLOGISTS | 2016 | second_quarter | PHA | Physician Payment Rates, Electronic Health Records Incentives program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2016-07-19T11:16:17.443000-04:00 | |
| 1849610 | CLOAKROOM ADVISORS LLC 12820600-0b15-4817-8da4-356934f049ca | Q2 | CLOAKROOM ADVISORS LLC | 401103204 | LINDEN CARE LLC | 2016 | second_quarter | PHA | Congressional delegation outreach and education on issues related to speciality pharmacies | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-19T11:17:29.287000-04:00 | |
| 1849665 | ELI LILLY AND COMPANY 4de7b503-dc24-4a5f-817c-a32bfedee1e2 | Q2 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2016 | second_quarter | PHA | Hospital discounts; 340B Program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 1840000 | 0 | 0 | 2016-07-19T11:20:06.880000-04:00 | |
| 1849687 | RUBICON ADVISORS, LLC 5efe5505-60e7-4628-9a94-c2551700cc99 | Q2 | RUBICON ADVISORS, LLC | 315091 | DR. REDDY'S LABORATORIES, LTD | 2016 | second_quarter | PHA | Food and Drug Administration, Generic Drug User Fees, NHI, DEA | Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 45000 | 0 | 0 | 2016-07-19T11:21:26.287000-04:00 | |
| 1849712 | AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 3d4dd809-7301-4f1b-9e06-f52d0f3cae13 | Q2 | AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES | 2321 | AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES | 2016 | second_quarter | PHA | ACA and tax treatment of health care, alternatives to the ACA, ending tax exlusion for employer-provided health care, policies to rein in prescription drug costs NIH march-in rights under Dole-Bayh Act | HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Social Security Administration (SSA),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office | 650000 | 0 | 0 | 2016-07-19T11:23:46.380000-04:00 | |
| 1849822 | CAPITOL COUNSEL LLC cc70f37c-4ce7-407f-bf9d-32aef03f25e1 | Q2 | CAPITOL COUNSEL LLC | 313715 | AMERICAN HEALTH CARE ASSOCIATION | 2016 | second_quarter | PHA | S.1560: Nursing Home Resident Pain Relief Act of 2011. S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012. S.621: Safe Prescribing Act. Continued monitoring of Nurse Agent and Drug disposal issue | HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2016-07-19T11:29:57.913000-04:00 | |
| 1850007 | HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC 8ae9a86e-6cdf-480e-b7ee-e065be9fe1de | Q2 | HECHT LATHAM SPENCER & ASSOCIATES, INC., FORMERLY KNOWN AS HECHT SPENCER & ASSOC | 17966 | ELI LILLY AND COMPANY | 2016 | second_quarter | PHA | Issues relating to prescription drug prices. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-19T11:46:58.290000-04:00 | |
| 1850150 | RAMPY NORTHRUP LLC b8459cd1-70d7-438d-96f3-0bdcbb0be554 | Q2 | RAMPY NORTHRUP LLC | 401103289 | ACADEMY OF MANAGED CARE PHARMACY | 2016 | second_quarter | PHA | Dissemination of pharmacoeconomic information. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-19T12:01:26.887000-04:00 | |
| 1850399 | KOUNTOUPES DENHAM CARR & REID, LLC 6615965d-6462-448d-b24f-fc293905b3af | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2016 | second_quarter | PHA | General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. Issues related to H.R. 6, "21st Century Cures" and the Senate Medical Innovations package. Issues related to the over the counter drug monograph process. Issues related to the disposal of unused over the counter drugs. Issues related to the FDA regulatory process by which prescription medicines are switched to Over the Counter. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-19T12:23:36.233000-04:00 | |
| 1850759 | BROWN RUDNICK LLP 081c0b5e-f5bf-4bca-8eed-86dd6c65a5e3 | Q2 | BROWN RUDNICK LLP | 287895 | HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC | 2016 | second_quarter | PHA | S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 524 Comprehensive Addiction and Recovery Act (CARA); H.R. 5046- Comprehensive Opioid Abuse Reduction Act of 2016: H.R. 4641 relating to the establishment of an inter-agency task force on best practices for pain management and prescribing | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-19T13:06:26.257000-04:00 | |
| 1850936 | TCH GROUP, LLC fa7be526-e5a2-4246-b5e4-be8b9e2d425b | Q2 | TCH GROUP, LLC | 51478 | CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) | 2016 | second_quarter | PHA | S.483, Ensuring Patient Access and Effective Drug Enforcement Act of 2015 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2016-07-19T13:27:20.740000-04:00 | |
| 1851420 | AVENUE SOLUTIONS b9538182-15e4-4abf-839c-6ae8f97c785b | Q2 | AVENUE SOLUTIONS | 72111 | JAZZ PHARMACEUTICALS, INC. | 2016 | second_quarter | PHA | S. 3056, Creating and Restoring Equal Access to Equivalent Samples Act of 2016 (CREATES Act of 2016) | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-19T14:17:27.373000-04:00 | |
| 1851464 | ISEMAN & ASSOCIATES LLC 46e26da3-f65b-4531-9b63-a09d464ab160 | Q2 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2016 | second_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2016-07-19T14:22:07.843000-04:00 | |
| 1851468 | AVENUE SOLUTIONS fbb2f94f-b2a0-4b64-808c-d567d349ee28 | Q2 | AVENUE SOLUTIONS | 72111 | MOMENTA PHARMACEUTICALS, INC. | 2016 | second_quarter | PHA | issues related to biogenerics and Medicare reimbursement | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-19T14:23:14.030000-04:00 | |
| 1851480 | AVENUE SOLUTIONS d3c9fb26-0b4d-49cc-a52a-e5b7a784e890 | Q2 | AVENUE SOLUTIONS | 72111 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 2016 | second_quarter | PHA | issues related to biosimilars; H.R. 6, 21st Century Cures Act | 80000 | 0 | 0 | 2016-07-19T14:25:24.453000-04:00 | ||
| 1851907 | 340B HEALTH 0b904349-34ab-4e97-8466-fca4947ef8a4 | Q2 | 340B HEALTH | 316434 | 340B HEALTH | 2016 | second_quarter | PHA | The 340B Drug Pricing program, Health Resources and Services Administration 340B Drug Pricing Program Omnibus Guidance, FY17 Labor Health and Human Services Appropriations, Delaware Medicaid State Plan Amendment, CMS Medicaid and CHIP Managed Care Final Rule, CMS Covered Outpatient Drug Final Regulation,340B Ceiling Price and Manufacturer Civil Monetary Penalties Regulation, Hospital Outpatient PPS Policy Changes and Payment Rates and Ambulatory Surgical Center Payment System Policy Changes and Payment Rates,Part B Drug Payment Model Proposed Rule | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 193496 | 0 | 0 | 2016-07-19T14:59:38.567000-04:00 | |
| 1852264 | TEVA PHARMACEUTICALS USA, INC. ba02f505-c0d5-4ac9-b415-aa49c4927dec | Q2 | TEVA PHARMACEUTICALS USA, INC. | 76695 | TEVA PHARMACEUTICALS USA INC | 2016 | second_quarter | PHA | Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 930000 | 0 | 0 | 2016-07-19T15:26:38.647000-04:00 | |
| 1852334 | ARNOLD & PORTER KAYE SCHOLER LLP 507a1899-8923-42ed-a01d-91debcc6dc73 | Q2 | ARNOLD & PORTER KAYE SCHOLER LLP | 4301 | INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS | 2016 | second_quarter | PHA | Issues related to the regulation of the practice of pharmacy compounding. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-19T15:33:45.133000-04:00 | |
| 1852603 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d396bc14-1e83-4308-8452-98d2dee9b1fb | Q2 | HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) | 28776 | HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) | 2016 | second_quarter | PHA | Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483, S. 524, H.R. 953, H.R. 4641); 21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 306000 | 0 | 0 | 2016-07-19T16:01:55.557000-04:00 | |
| 1852826 | ASSOCIATION FOR ACCESSIBLE MEDICINES 04883984-327c-45e8-858d-f6df6bfaad37 | Q2 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 16032 | ASSOCIATION FOR ACCESSIBLE MEDICINES | 2016 | second_quarter | PHA | Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA). Labeling of Generic Drugs. Biosimilars Naming. Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products. Prescription Drug Costs. H.R.2841: FAST Generics Act of 2015. H.R.1314: Bipartisan Budget Act of 2015. Drug Importation. Risk Evaluation and Mitigation Strategies (REMS). Biologic Exclusivity. Biologics Price Competition and Innovation Act (BPCIA). S.2615: Increasing Competition in Pharmaceuticals Act. Pharmaceutical exclusivity. H.R.4931: Pharmaceutical Stewardship Act of 2016. H.R.953: Comprehensive Addiction and Recovery Act of 2015 (CARA). S.3056: CREATES Act of 2016. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 802333 | 0 | 0 | 2016-07-19T16:16:23.513000-04:00 | |
| 1853058 | RED+BLUE STRATEGIES 18b5cce0-49f2-404e-942b-0da6787fe176 | Q2 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2016 | second_quarter | PHA | S. 524 - the Comprehensive Addition and Recovery Act- issues related to ensuring best prescribing practices for opioids in the country and solutions developed by BCBSMA to combat abuse. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-07-19T16:36:52.017000-04:00 | |
| 1853199 | KOUNTOUPES DENHAM CARR & REID, LLC 0f609380-cf79-4e36-8a28-1a3a2dd8a08a | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2016 | second_quarter | PHA | General education about the pharmacy benefit manager/pharmacy industry. Issues related to H.R. 6, The 21st Century Cures Act and the Senate Innovations for Healthier Americans Initiative. Affordability and pricing of pharmaceuticals and S. 524 The Comprehensive Addiction and Recovery Act of 2015. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2016-07-19T16:51:46.783000-04:00 | |
| 1853227 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) 2752fb55-3b67-4a1e-9cc1-52f09b5ea5cb | Q2 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA MNK PHARMACEUTICALS) | 401095056 | ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS (FKA ST SHARED SERVICES LLC DBA | 2016 | second_quarter | PHA | Highly enriched to Low enriched uranium (HEU-LEU) related issues for Nuclear Medicine (no specific bill number); 21st Century CURES Act (H.R.6); Issues related to "real world" clinical evidence; Issues related to Opioid abuse and alternatives to opioids (no specific bill number). | Energy, Dept of,HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 410000 | 0 | 0 | 2016-07-19T16:55:29-04:00 | |
| 1853271 | MR. GALEN RESER 7795e987-a48c-4db5-beb7-c6b2d8a76008 | Q2 | MR. GALEN RESER | 401055978 | PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) | 2016 | second_quarter | PHA | Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2016-07-19T16:59:16.033000-04:00 | |
| 1853280 | GILEAD SCIENCES, INC. a20d59a4-c7bb-432f-92ef-71c67c32579d | Q2 | GILEAD SCIENCES, INC. | 287177 | GILEAD SCIENCES INC | 2016 | second_quarter | PHA | Coverage of pharmaceuticals, cost-sharing and other access issues; 21st Century Cures initiative; Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid and Affordable Care Act implementation; FDA issues and 340B. S. 3056: CREATES Act of 2016. | Commerce, Dept of (DOC),Defense, Dept of (DOD),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Veterans Affairs, Dept of (VA) | 760000 | 0 | 0 | 2016-07-19T17:00:26-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);